42results about "Calcium binding proteins" patented technology

Novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions are provided herein that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided herein.

Provided herein are methods and cell systems for production of a recombinant antibody in cells in which the antibody is directed against a target protein that is natively expressed as an intracellular protein in the cell. Also provided herein are modified cell lines for use in such methods in which the modified cell line is engineered to express a variant target protein that has a mutant epitope of the target epitope of an antibody.

The chimeric signal peptide for protein expression comprises an N region, a hydrophobic region, and a C region, wherein the N region and the C region are from the same signal peptide of a first protein, and the hydrophobic region is from the signal peptide of a second protein, and the first protein is different from the second protein. The first and second proteins can be independently selected from the group consisting of BM40, IL2, HA, insulin, CD33, IFNA2, IgGK leader, AZU, and SEAP.

The present disclosure provides constructs comprising a coding sequence operably linked to a promoter which expresses the polynucleotide in an outer hair cell, wherein the coding sequence encodes a polypeptide (e.g., a heterologous polypeptide). Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and / or deafness.

The invention relates to a mutant calreticulin for diagnosis of myeloid malignant tumors. A method for diagnosing myeloid malignancies comprising determining the presence of a mutant allele of a calreticulin gene is disclosed. In addition, genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are also subject matter of the invention. Furthermore, the invention relates to the medical use of inhibitors of the mutant calreticulin.

The present invention relates generally to methods for preventing and / or treating myeloproliferative disorders. More specifically, the myeloproliferative disorders are those associated with the presence of a frameshift mutation in the calreticulin (CALR) gene of a cell involved in the myeloproliferative disorders. The present invention also relates to immunological agents, such as antibodies, to calreticulin, methods for preventing and / or treating myeloproliferative diseases using the immunological agents, and chimeric antigen receptors having extracellular domains based on antibodies to calreticulin.

Novel chimeric peptides comprise an N-cadherin binding domain for binding N-cadherin, which is expressed on the surface of cells, in particular smooth muscle cells, and a fibronectin- binding domain, which binds surrounding extracellular matrix and a binding site for fibronectin. The chimeric peptides can be loaded on to nanoparticles, suitably degradable polar hydrophobic ionic polyurethane (D-PHI) nanoparticles for delivery, which can be incorporated into coatings for medical devices, including stents and balloons.

Provided are a use of recombinant calreticulin in hair growth, hair breeding, hair protection or anti-hair loss and a related product. The recombinant protein is derived from the full length of calreticulin or a fragment thereof, and has the functions of treating hair loss and improving hair by means of injection or application. Therefore, calreticulin is expected to be developed into an effective method and means for treating hair loss and improving hair.

Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided.

This invention discloses a lactobridged protein-derived calcium chelating peptide and its applications, belonging to the field of bioactive small molecule peptide technology. The calcium chelating peptide provided by this invention is safe and non-toxic, exhibiting better physicochemical activity compared to traditional calcium supplements. Its calcium chelating capacity reaches over 419.36 μg / mg, and it can promote calcium transport in the Caco-2 cell monolayer, thereby improving calcium absorption and bioavailability in the human body, making it suitable for use as a calcium supplement. This invention can develop a new protein source for calcium supplements and makes a significant contribution to the high-value utilization of dairy products.

The present invention provides novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions that are useful as agents, for example, in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. The invention further provides a corresponding method and application.

The present disclosure provides constructs that include a coding sequence operably linked to a promoter that expresses a polynucleotide in an outer hair cell, the coding sequence encoding a polypeptide (e.g., a heterologous polypeptide). Exemplary constructs include AAV constructs. Also provided are methods of using the disclosed constructs for the treatment of hearing loss and / or hearing loss.

Provided herein are methods and compositions for treating and / or preventing recurrent Clostridium difficile infection (rCDI), neutropenia, cardiovascular disease (e.g., atherosclerosis and / or stroke), asthma, and / or cancer involving administering to a subject a pharmaceutical composition comprising a purified bacterial mixture.

Novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions are provided herein that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided herein.

This disclosure provides expression systems comprising secretion signals that promote production and / or secretion of proteins of interest, as well as one or more polynucleotides encoding chaperone proteins (e.g., CRT and / or PDIA3) which, as demonstrate herein, enhance production and / or secretion of proteins. Moreover, genetically modified host cells comprising these expression systems are capable of producing high levels of protein of interest, such as bovine lactoferrin (bLF), bovine lactoglobulin (bLG), or ovalbumin (Ova).

The present invention relates to improved protein-based biosensors that are suitable for detection of one or more target molecules in a sample. The biosensors are fully-reversible with dynamic ranges suitable for analytic and diagnostic applications. The biosensors of the present invention may be used in synthetic biology, for example in constructing artificial cellular or extracellular signalling networks.

The invention relates to the technical field of bioengineering, in particular to an S100A4 protein for regulating and controlling immune response as well as a preparation method and application of the S100A4 protein. According to the invention, a HaloTag-S100A4 eukaryotic expression vector is constructed, fusion protein is expressed in cells, resin specificity affinity capture is utilized, protease cleavage release is carried out, and finally the high-purity S100A4 protein is obtained. The S100A4 protein prepared by the invention has excellent biological activity and structural integrity. Due to the adoption of the eukaryotic expression system, the protein can complete correct post-translational modification, the conformation of the protein is highly consistent with that of natural protein, and the protein has high activity without complex renaturation steps. Compared with commercially available prokaryotic expression or naturally extracted S100A4 protein, the protein obtained by the invention has higher purity and fewer impurities, and interference of exogenous components on experimental results is avoided.

The present application provides fusion proteins comprising an interleukin-15 (IL-15) sequence and an interleukin-15 receptor alpha (IL-15R alpha) sequence, the fusion proteins having an endoplasmic reticulum (ER) retention sequence and / or a myristicylation sequence.

This application includes a mammalian mRNA expression construct for producing a protein or polypeptide, the mammalian mRNA expression construct including a modified Munc13-1 molecule.

The present invention provides novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions for use as agents, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. The invention further provides a corresponding method and application.

Disclosed herein are compositions comprising a peptide containing a CD44 binding site and / or a calcium binding site, as well as methods for stimulating hair growth by using the compositions.

The application provides a thrombocytosis and thrombosis zebrafish model and a construction method and application thereof, and belongs to the technical field of biology. CALR del52 The transgenic zebrafish is obtained, and the transgenic zebrafish is added with a thrombus inducer of arachidonic acid to induce and construct; CALR del52 The nucleotide sequence is shown as SEQ ID NO. 1; the thrombocytosis and thrombosis disease zebrafish model provided by the application can be used for screening of anti-thrombus treatment drugs, has a short experimental cycle, a small dosage, and is favorable for high-throughput screening of trace anti-thrombus active natural products.

The presently claimed and described technology provides vaccine compositions comprising at least two mutant-calreticulin (CALR)-peptides, wherein the at least two peptides have overlapping sequences and methods for administration of the vaccine compositions to induce or elicit an antitumor response or improve or enhance antitumor T cell immunity and methods of preventing, treating, reducing, or slowing progression or development of a hematological malignancy in a subject with a calreticulin mutation.

Provided are fusion proteins comprising an interleukin- 15 (IL-15) sequence and an interleukin- 15 receptor alpha (IL-15Ra) sequence, with an endoplasmic reticulum (ER) retention sequence and / or a myristoylation sequence.

The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.

The invention belongs to the technical field of biotechnology and neuroscience, and particularly relates to application of CAB39 protein in promotion of neural stem cell proliferation and preparation of drugs for treating nervous system diseases. Research finds that CAB39 protein can interact with STAT3 protein, promote phosphorylation activation of the STAT3 protein, activate transcription of downstream proliferation related genes and specifically promote proliferation of neural stem cells for the first time, and verifies that the CAB39 protein can efficiently and safely promote proliferation of neural stem cells in vivo. Therefore, the CAB39 protein can be used for promoting the proliferation of the neural stem cells in a non-treatment destination, can also be used for preparing medicines for treating nervous system diseases, has the application value of regulating and controlling the proliferation of the neural stem cells in vitro, also has potential clinical transformation value, and can be applied to the fields of nerve injury repair, stem cell transplantation, medicine screening and the like.

The present disclosure generally relates to systems and methods for treating and preventing diseases or conditions such as aging, atherosclerosis, obesity, viral disease, etc. These may be treated, according to some embodiments, by activation of an immune response within a subject. In some embodiments, for example, aging may be treated or prevented by removal of senescent cells by the immune system. In some embodiments, atherosclerosis may be treated or prevented by removal of plaque by the immune system. In some embodiments, obesity may be treated by removal of fat cells by the immune system. In some embodiments, viral diseases may be treated by removal of viruses by the immune system. Exemplary viral diseases include diseases caused by SARS-CoV-2 and HIV, among others.

Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.